Clinical Toxicology · 2021 · 37 citations · 12 references
PharmacyPharmacologyToxicologyClinical PharmacologyHepatotoxicologyPoisoning ManagementDrug ToxicityFomepizole TherapyHepatic ToxicityHepatotoxicity ManagementN-acetylcysteine TherapyOverdose ManagementAcetylcysteine TherapyAcute Liver Failure TreatmentC-jun N-terminal Kinase SignalingJun N-terminal Kinase SignalingManagement Of High-risk PatientsN-acetylcysteine PharmacologyOverdose ToxicityPoisoning Case Series
INTRODUCTION: Acetaminophen (N-acetyl-para-aminophenol or APAP) is the leading cause of acute liver failure worldwide. Standard therapy for APAP overdose is with IV N-acetylcysteine (NAC). However, overdose patients treated with NAC can still incur hepatotoxicity in some circumstances. Fomepizole has proven safety in methanol and ethylene glycol poisoning and is a potent CYP2E1 and c-Jun-N-terminal Kinase (JNK) inhibitor that is effective even in the metabolic phase. METHODS: We present a prospective case series of 14 consecutive, high-risk patients who had elevated APAP levels after overdose who were treated with fomepizole as an adjunct to standard IV-NAC. The attending toxicologist utilized clinical judgement to determine the use of fomepizole, especially if APAP levels persisted due to altered half-life or risk factors for toxicity. RESULTS: There were no unfavorable outcomes in any patient, which were better than expected. CONCLUSIONS: This case series has demonstrated the safety of fomepizole in high-risk APAP overdose. The efficacy of fomepizole needs to be further elucidated through controlled clinical trials on a larger scale. In massive APAP overdoses, fomepizole should be considered as an adjunct due to the known failure rate of NAC and the safety profile of fomepizole.
12
Acetaminophen Hepatotoxicity: The First 35 Years
Barry H. Rumack · Journal of Toxicology Clinical Toxicology · 2002 · 336 citations
Pharmacy, Pharmacology, Toxicology +17